# US 8,784,818 B2 · Anti-VEGFR-3 antibody compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,818 B2
- Document ID: US8784818B2
- Status: Granted
- Kind: B2
- Application number: 13/888,716
- Filed: 2013-05-07
- Published: 2013-10-24
- Granted: 2014-07-22
- Earliest claimed: 2010-09-07
- Assignees: ImClone LLC
- Applicants: ImClone LLC
- Inventors: Bronislaw Pytowski; Krishnadatt Persaud; Nathalie Zayek
- Web page: https://patentgrep.com/patent/US8784818B2

## CPC

- C07K 16/30: from tumour cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease.

## Claims

### Claim 1

A method of treating cancer in a mammal in need thereof, comprising administering to said mammal an antibody that binds to human VEGFR-3 comprising a LCDR1 of SEQ ID NO: 1, a LCDR2 of SEQ ID NO: 2, a LCDR3 of SEQ ID NO: 3, a HCDR1 of SEQ ID NO: 6, a HCDR2 of SEQ ID NO: 7 and a HCDR3 of SEQ ID NO: 8, wherein the cancer is colon cancer.

### Claim 2 (depends on 1)

The method of claim 1, further comprising administering another anti-cancer treatment, wherein said anti-cancer treatment is oxaliplatin.

### Claim 3

A method of treating cancer in a mammal in need thereof, comprising administering to said mammal an antibody that binds to human VEGFR-3 comprising a light chain variable region of SEQ ID NO: 5 and a heavy chain variable region of SEQ ID NO: 10, wherein the cancer is colon cancer.

### Claim 4 (depends on 3)

The method of claim 3, further comprising administering another anti-cancer treatment, wherein said anti-cancer treatment is oxaliplatin.

### Claim 5

A method of treating cancer in a mammal in need thereof, comprising administering to said mammal an antibody that binds to human VEGFR-3, comprising two light chains of SEQ ID NO: 15 and two heavy chains of SEQ ID NO: 16, wherein the cancer is colon cancer.

### Claim 6 (depends on 5)

The method of claim 5, further comprising administering another anti-cancer treatment, wherein said anti-cancer treatment is oxaliplatin.